TRIM-edicine

CompanyUnited States

TRIM-edicine develops one asset, preclinical (MG53 in muscle injury). Mostly protein or enzyme; based in the United States.

1
Asset
Furthest stage: Preclinical; 1
Grant: 0
Trials: 0
Signals

Pipeline

1

MG53
Promotes cell membrane repair to protect injured tissues and support regeneration.
Preclinical, Protein or enzyme, muscle injury

Full company profiles: pipeline, trials, funding and people.

In the full profile

People1
Signals1

Papers

MG53 suppresses NF-κB activation to mitigate age-related heart failure
JCI insight, Jul 23, 2021
Sustained elevation of MG53 in the bloodstream increases tissue regenerative capacity without compromising metabolic function
Nature communications, Oct 11, 2019